---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-171026"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-06-09T23:59:59+00:00"
generated_at: "2026-06-25T03:12:40.654871+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics reports 2022 annual meeting vote results

## Summary
- Elected Kate Haviland, Katina Dorton, Robert Gould as Class III directors for three-year term ending 2025.
- Director vote results: Haviland 25,135,506 for / 5,600,007 withheld; Dorton 27,146,569 for / 3,588,944 withheld; Gould 26,665,833 for / 4,069,680 withheld.
- Ratified Ernst & Young LLP as independent auditor for FY2022: 34,538,061 for, 20,325 against, 10,946 abstain.

## SEC filing metadata
- accession: 0001193125-22-171026
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/0001193125-22-171026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/d334925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-171026
- JSON: https://secwatch.observer/filing/0001193125-22-171026.json
- Plain text: https://secwatch.observer/filing/0001193125-22-171026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.